PacBio Q3 Loss Widens Marginally as CFO Exits; Guidance Narrowed to $155M-$160M
PACB has more than doubled off its 52-week low of $1.07.
Summary
PacBio posted a $37.8M Q3 loss on $40.6M revenue with gross margin down to 33%, narrowed 2026 revenue guidance to $155M-$160M, and disclosed that CFO Jim Gibson has stepped down with the CEO taking the interim CFO role.
Key Events · Earnings and Guidance · PACB
-
Q3 Revenue $40.6M, Loss $37.8M
Revenue rose to $40.6M from $38.4M a year earlier, but GAAP net loss was $37.8M, or $0.12 per share, versus $38.0M a year ago.
-
Gross Margin Falls to 33%
GAAP gross margin dropped to 33% from 41%, and non-GAAP to 36% from 42%, primarily on higher memory costs and Vega manufacturing transition costs.
-
CFO Out, CEO Takes Interim Role
Jim Gibson stepped down as CFO effective November 3, 2026 and moves to an advisory role through March 31, 2027 with a $500,000 lump-sum severance; CEO Mark Van Oene is interim CFO and Bill Meyer is the new Chief Accounting Officer.
-
Guidance Narrowed to $155M-$160M
Full-year 2026 revenue is now expected at $155M-$160M, tightening the $155M-$165M range set when guidance was cut in August 2026.
Analysis · PACB · Industrial Applications And Services
Revenue of $40.6M was up 5.5% year over year, but gross margin fell to 33% GAAP (36% non-GAAP) from 41% a year ago, driven by higher memory costs and Vega manufacturing transition costs — the company is selling more instruments while making less on each one. The bigger governance story is the CFO exit: Jim Gibson stepped down the day before this filing and the CEO is now also interim CFO, with a $500,000 severance and a search for a permanent finance chief underway. Cash fell to $199.4M from $298.7M a year earlier while $643M of convertible notes sit on the balance sheet and stockholders' equity has turned negative, so the runway question is now the central issue for holders.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PACB was trading at $2.68 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $792.6M. The 52-week trading range was $1.07 to $3.44. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.